TY - JOUR
T1 - Intravitreal acetazolamide implant for pseudophakic cystoid macular edema
AU - Jorge, Rodrigo
AU - Villela, Isabela Franco
AU - Fernandes, Christian
AU - de Azevedo Bastos, Thais Marino
AU - Scott, Ingrid U.
AU - da Silva Cunha, Armando
AU - Fialho, Silvia Ligório
AU - da Silva, Pedro Henrique Reis
AU - Messias, André
N1 - Funding Information:
FAPESP provided financial support in the form of research grant for André Messias and Rodrigo Jorge. The sponsor had no role in the design or conduct of this research.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/8
Y1 - 2023/8
N2 - Background: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases. Report: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 μg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication. Conclusion: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.
AB - Background: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases. Report: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 μg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication. Conclusion: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.
UR - http://www.scopus.com/inward/record.url?scp=85163364297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163364297&partnerID=8YFLogxK
U2 - 10.1007/s10633-023-09939-6
DO - 10.1007/s10633-023-09939-6
M3 - Article
C2 - 37369909
AN - SCOPUS:85163364297
SN - 0012-4486
VL - 147
SP - 71
EP - 75
JO - Documenta Ophthalmologica
JF - Documenta Ophthalmologica
IS - 1
ER -